Analyst Ratings for RAPT Therapeutics
RAPT Therapeutics Questions & Answers
The latest price target for RAPT Therapeutics (NASDAQ: RAPT) was reported by Capital One on September 21, 2022. The analyst firm set a price target for $48.00 expecting RAPT to rise to within 12 months (a possible 95.76% upside). 9 analyst firms have reported ratings in the last year.
The latest analyst rating for RAPT Therapeutics (NASDAQ: RAPT) was provided by Capital One, and RAPT Therapeutics initiated their overweight rating.
Analysts arrive at stock ratings after doing extensive research, which includes going through public financial statements, talking to executives and customers of RAPT Therapeutics, and listening in to earnings conference calls. Most analysts do this every three months, so you should get 4 ratings per company per firm each year. The last rating for RAPT Therapeutics was filed on September 21, 2022 so you should expect the next rating to be made available sometime around September 21, 2023.
While ratings are subjective and will change, the latest RAPT Therapeutics (RAPT) rating was a initiated with a price target of $0.00 to $48.00. The current price RAPT Therapeutics (RAPT) is trading at is $24.52, which is within the analyst’s predicted range.
Browse analyst ratings and price targets on all stocks.